Abstract Rationale Multiple rapid diagnostic aids for sepsis identification have received regulatory approval in recent years, including BV (MeMed), Immunoscore (Prenosis), Intellisep (Cytovale), Monocyte Distribution Width (MDW, Beckman Coulter), Septicyte (ImmuneExpress), and TriVerity (Inflammatix). We sought to assess the uptake of these novel tests in Michigan hospitals. Methods The Michigan Hospital Medicine Safety Consortium (HMS) is a multi-hospital collaborative quality initiative sponsored by Blue Cross Blue Shield of Michigan. Participating hospitals complete a twice-yearly survey about structures and processes of care to inform statewide quality improvement work. The designated HMS representative for each hospital completes the survey, compiling responses from relevant staff at their institution. The spring 2025 survey asked about the availability of rapid diagnostic aids for sepsis identification and how these tests are used if available. Results All 68 participating hospitals (100%) completed the HMS spring 2025 survey. Five hospitals (7.4%) reported having the MDW test available. No other rapid diagnostic aid for sepsis identification was available at any HMS hospital. Among the 5 hospitals with MDW, 4 automatically measured MDW with every complete blood count with differential in the emergency department, whereas the remaining hospital did not specify when MDW was measured. Incorporation of MDW into clinical decision-making was left to clinician discretion. No hospitals reported sepsis screening or treatment protocols that incorporated novel rapid diagnostic aids for sepsis. Conclusions There has been limited uptake of rapid diagnostic aids for sepsis identification into clinical practice to date. These findings highlight a gap between regulatory approval and clinical adoption, and suggests the need for studies to evaluate the clinical impact of rapid diagnostic aids for sepsis and barriers to their implementation. This abstract is funded by: Blue Cross Blue Shield of Michigan
Deshpande et al. (Fri,) studied this question.